SterRx Recalls 240 Lots of 12 Products
Equipment and process issues could lead to a lack of sterility.
SterRx is recalling about 240 lots of 12 different products. The recall is being made because of due equipment and process issues that could lead to a lack of sterility. To date, SterRx has not received reports of adverse events associated.
These lots were distributed between December 2020 and October 2021.
The products impacted include:
- 1mg/mL Midazolam in 0.9% Sodium Chloride
- Fentanyl in 0.9% Sodium Chloride
- 1mg/mL Morphine Sulfate in 0.9% Sodium Chloride
- 1mg/mL Morphine Sulfate in 5% Dextrose
- 125mg Diltiazem HCL in 0.7% Sodium Chloride
- 125mg Diltiazem HCL in 5% Dextrose
- Norepinephrine in 0.9% Sodium Chloride
- Norepinephrine in 5% Dextrose
- Epinephrine in 0.9% Sodium Chloride
- Phenylephrine in 0.9% Sodium Chloride
- 150mEq Sodium Bicarbonate in 5% Dextrose
- 200mg Succinylcholine Chloride in 0.9% Sodium Chloride
Those with questions should call (518) 324-7983 or email Recall@sterrx.com.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
